Directory
>
Alex Zhavoronkov
Alex Zhavoronkov
Scientific Advisor | Insilico Medicine
New York, New York, United States
Alex Zhavoronkov
Summary
Alex Zhavoronkov is a visionary leader in the field of biomedicine and artificial intelligence, currently serving as the Founder and CEO of Insilico Medicine, a pioneering company in generative AI drug discovery. With a strong academic background including a PhD in Physics and a Master's in Biotechnology, he has dedicated his career to advancing the understanding of aging and longevity through innovative research and technology. Alex has been instrumental in raising over $400 million for Insilico, which has successfully launched multiple clinical trials and developed several promising drug candidates. He is also the founder of the Aging Research and Drug Discovery conference, fostering collaboration among top experts in the field. His commitment to sustainability and peace reflects his belief in the power of science to unite people for the greater good. With a diverse portfolio of roles across various organizations, Alex's influence extends beyond his current position, making him a key figure in the biogerontology community.
Alex Zhavoronkov
Work Experience
Scientific Advisor at
Haut.AI
February 2017 - Present
Founder and CEO at
Insilico Medicine
January 2014 - Present
Chief Longevity Officer at
Deep Longevity
November 2020 - February 2024
Founder and CEO at
Deep Longevity
January 2020 - November 2020
Founder at
The International Aging Research Portfolio Non Profit
October 2008 - December 2018
Advisor at
Biogerontology Research Foundation
February 2008 - January 2018
International Adjunct Professor at
Moscow Institute of Physics and Technology (State University) - MIPT, Phystech
November 2013 - January 2015
Chief Technology Officer at
Neurog
January 2009 - September 2014
Head of the Regenerative Medicine Laboratory at
Center For Pediatric Hematology Oncology And Immunology
December 2012 - January 2014
Head of the Bioinformatics Laboratory at
Center For Pediatric Hematology Oncology And Immunology
October 2011 - January 2013
Consultant at
Sequenom
March 2009 - January 2011
Director, BD at
Colby Pharmaceutical Company
January 2008 - January 2009
Director, BD at
GTCbio
January 2007 - January 2008
Director at
AMD
January 2004 - January 2006
Regional Manager, Eastern Europe at
AMD
January 2003 - January 2005
Manager at
AMD
January 2002 - January 2003
Product Marketing Engineer at
Microsemi Corporation
January 2001 - January 2002
Alex Zhavoronkov
Education
Queen's University, Bachelor Of Commerce (Honors)
Moscow State University, Phd
Johns Hopkins University, Master Of Science
Queen's University, Bachelor Of Science
Canadian Securities Institute, Certificate
NCBI, NLM, National Institutes of Health, Certificate
Frequently Asked Questions about Alex Zhavoronkov
What is Alex Zhavoronkov email address?
Alex Zhavoronkov's primary email address is ****@deeplongevity.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Alex Zhavoronkov work for?
Alex Zhavoronkov is a Scientific Advisor at Insilico Medicine, a company specializing in Commercial physical research.
Where Alex Zhavoronkov graduated from?
Alex Zhavoronkov holds a degree in Finance, Management Of Information Systems from Queen's University.
How can I directly contact Alex Zhavoronkov?
To contact Alex Zhavoronkov directly, you can use the email address ****@deeplongevity.com. Complete contact information is available upon registration with Muraena.
Is Alex Zhavoronkov an immigrant?
Yes, Alex Zhavoronkov is an immigrant and currently based in United States
Who is Alex Zhavoronkov?
Alex Zhavoronkov is a visionary leader in the field of biomedicine and artificial intelligence, currently serving as the Founder and CEO of Insilico Medicine, a pioneering company in generative AI drug discovery. With a strong academic background including a PhD in Physics and a Master's in Biotechnology, he has dedicated his career to advancing the understanding of aging and longevity through innovative research and technology. Alex has been instrumental in raising over $400 million for Insilico, which has successfully launched multiple clinical trials and developed several promising drug candidates. He is also the founder of the Aging Research and Drug Discovery conference, fostering collaboration among top experts in the field. His commitment to sustainability and peace reflects his belief in the power of science to unite people for the greater good. With a diverse portfolio of roles across various organizations, Alex's influence extends beyond his current position, making him a key figure in the biogerontology community.
Alex`s contact details
****@deeplongevity.com
****@insilico.com
***********@jhu.edu
*@insilicomedicine.com
Colleagues
Board of Trustees
President
Global Head of AI Platforms, VP Insilico Medicine